Side-by-side · Research reference
HGH 191AAvsTesamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED0/75 cited
BFDA-ApprovedFlagship27/68 cited
HGH 191AA
Recombinant hGH · FDA-Approved
0.024–0.034 mg/kg/dayPediatric GHD dose
2–4 hoursPlasma half-life
191 AASequence length
SQ · Daily · Evening preferred
Tesamorelin
GHRH Analogue · FDA-Approved
SQ · Abdomen · Once Daily
01Mechanism of Action
Parameter
HGH 191AA
Tesamorelin
Primary target
Growth hormone receptor (GHR) — JAK2/STAT5 pathway
Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010
Pathway
GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects
GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007
Downstream effect
Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation
Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010
Feedback intact?
No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility
Yes — physiological pulsatility preserved
Origin
Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue
Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010
Antibody development
Rare — <2% develop binding antibodies, typically non-neutralizing
~50% after 26 wks (non-neutralising in most)Sévigny 2018
02Dosage Protocols
Parameter
HGH 191AA
Tesamorelin
Pediatric GHD
0.024–0.034 mg/kg/day SQ
6–7× per week dosing typical. Brand-specific ranges.
—
Adult GHD
0.004–0.016 mg/kg/day SQ
Start low, titrate based on IGF-1 levels.
—
Turner syndrome
0.045–0.050 mg/kg/day SQ
—
Idiopathic short stature
0.037 mg/kg/day SQ
—
AIDS wasting
0.1 mg/kg/day SQ (high-dose)
Short-term indication. Monitor glucose.
—
Frequency
Once daily, typically evening
Evening administration mimics physiological GH pulse.
Once daily (morning or pre-sleep)
Aligns with natural GH pulse.
Monitoring
IGF-1, glucose, thyroid function, bone age (children)
—
Duration
Years (children until epiphyseal closure); indefinite (adult GHD)
12–52 weeks
VAT returns within months of stopping.
Reconstitution
—
Sterile water per labeling
Preserved at 2–8 °C after reconstitution.
Timing
—
Empty stomach, pre-sleep preferred
03Metabolic / Fat Loss Evidence
Parameter
HGH 191AA
Tesamorelin
Primary fat target
Visceral and subcutaneous adipose tissue
Visceral adipose tissue (VAT) — abdominal
Mechanism
Lipolysis via hormone-sensitive lipase activation, FFA oxidation
—
Effect on lean mass
Significant lean mass increase (protein synthesis, nitrogen retention)
Modest lean mass preservation / slight increase
Insulin sensitivity
Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss
Neutral to slight impairment (monitor HbA1c)Clarke 2018
IGF-1 elevation
Dose-dependent, significant — primary anabolic mediator
—
Glucose metabolism
Hyperglycemia risk, especially high doses (AIDS wasting)
Generally neutral; 4.5% HbA1c elevation riskClarke 2018
Body composition
↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)
—
Clinical context
FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.
—
Effect reversibility
—
VAT returns within months of stopping
Key publication
—
Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007Falutz 2010EGRIFTA® (tesamorelin for inje 2010
04Side Effects & Safety
Parameter
HGH 191AA
Tesamorelin
Injection site reaction
Lipohypertrophy, lipoatrophy, erythema (rotate sites)
Erythema, pruritus, redness (common)
Fluid retention / Edema
Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)
Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)
Glucose intolerance
Hyperglycemia, new-onset diabetes (anti-insulin effect)
HbA1c ↑ in 4.5% vs 1.3% placebo; HbA1c ≥6.5% hazard OR 3.3Clarke 2018
Intracranial hypertension
Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema
—
Slipped capital femoral epiphysis
SCFE risk in children — limp, hip/knee pain (requires surgery)
—
Scoliosis progression
Rapid growth may unmask/progress scoliosis (monitor spine in children)
—
Hypothyroidism
Central hypothyroidism unmasking or worsening (monitor TSH, free T4)
—
Cancer risk
Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).
Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010
Antibody formation
Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.
~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018
Pancreatitis
Rare. Higher risk in children with certain syndromes (Prader-Willi).
—
Gynecomastia
Adolescent males (physiological during puberty, may be exacerbated)
—
IGF-1 elevation
—
Dose-dependent; supraphysiological levels = discontinue
GI symptoms
—
Nausea, diarrhea (mild, transient)
Absolute Contraindications
HGH 191AA
- ·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
- ·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
- ·Diabetic retinopathy (active proliferative or severe non-proliferative)
- ·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
- ·Closed epiphyses (for growth indications)
Tesamorelin
- ·Active malignancy or history of treated cancer
- ·Pregnancy
- ·Hypersensitivity to tesamorelin or mannitol
- ·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)
Relative Contraindications
HGH 191AA
- ·Diabetes mellitus (monitor closely, may require insulin adjustment)
- ·Intracranial lesions or history of intracranial hypertension
- ·Scoliosis (monitor curve progression)
- ·Untreated hypothyroidism (treat before GH initiation)
- ·Severe obesity (assess OSA risk, cardiovascular status)
Tesamorelin
- ·Untreated diabetes (monitor HbA1c)
- ·Severe carpal tunnel syndrome
- ·Acute critical illness
05Administration Protocol
Parameter
HGH 191AA
Tesamorelin
1. Reconstitution (if lyophilized)
Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).
Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.
2. Injection site
Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.
Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.
3. Timing
Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.
Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.
4. Storage
Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.
5. Needle
27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.
27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.
6. Monitoring
Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.
—
06Stack Synergy
HGH 191AA
+ Ipamorelin
ModerateIpamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.
- HGH 191AA
- Standard dose per indication
- Ipamorelin
- 100–200 mcg SQ · morning (if used)
- Note
- Monitor IGF-1 closely; avoid supraphysiological levels
- Primary benefit
- Theoretical enhancement of pulsatility; limited clinical rationale
+ Tesamorelin
WeakTesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.
- Note
- Combination not recommended — choose one GH modality
- Primary benefit
- None — redundant mechanisms
Tesamorelin
+ Ipamorelin
StrongTesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.
- Tesamorelin
- 2 mg SQ · evening
- Ipamorelin
- 200–300 mcg SQ · same injection
- Frequency
- Once daily, pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep quality